Demand cancer drugs that truly help patients
Drug regulators and trial designs should assess benefits that actually matter to people with cancer, says Ajay Aggarwal.
Drug regulators and trial designs should assess benefits that actually matter to people with cancer, says Ajay Aggarwal.